Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?

Leukemia and Lymphoma

Volumn 50, Issue 3, 2009, Pages 471-474

  Papadakis, Vassilios ^a   Karakasis, Dimitri ^b   Sfikakis, Petros P ^c   Baltadakis, Ioannis ^b   Apostolidis, John ^b   Evangelou, Kostas ^d   Gorgoulis, Vassilis G ^d   Harhalakis, Nikolaos ^b  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; FLUDARABINE; HLA ANTIGEN; IMATINIB; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; DRUG WITHDRAWAL; HLA MATCHING; HUMAN; MALE; MUSCLE CRAMP; NAUSEA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POIKILODERMA; PRIORITY JOURNAL; PUVA; SCLERODERMA; SIBLING; SKIN BIOPSY; SPLENECTOMY; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PIPERAZINES; PYRIMIDINES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 67650918139     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802668881     Document Type: Article

References (16)

1. Skert, C., Patriarca, F., Sperotto, A., Cerno, M., Fili, C. Zaja, F. et al. (2006) Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoitic stem cell transplantation. Haematologica, 91, pp. 258-261.
2. Sfikakis, P. P., Gorgoulis, V. G., Katsiari, C. G., Evangelou, K., Kostopoulos, C. and Black, C. M. (2008) Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford), 47, pp. 735-737.
3. van Daele, P LA, Dik, W. A., Thio, H. B., van Hal, P Th, van Laar, J Am Hooijkaas, H. et al. (2008) Is imatinib mesylate a promising drug in sytemic sclerosis?. Arthritis Rheum, 58, pp. 2549-2552.
4. Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M. Fanning, S. et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2, pp. 561-566.
5. Daniels, C. E., Wilkes, M. C., Edens, M., Kottom, T. J., Murphy, S. J. Limper, A. H. et al. (2004) Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest, 114, pp. 1308-1316.
6. Wang, S., Wilkes, M. C., Leof, E. B. and Hirschberg, R. (2005) Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J, 19, pp. 1-11.
7. Rajkumar, V. S., Shiwen, X., Bostrom, M., Leoni, P., Muddle, J. Ivarsson, M. et al. (2006) Platelet-derived growth factor-β receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol, 169, pp. 2254-2265.
8. Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S. Druker, B. J. et al. (2000) Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther, 295, pp. 139-145.
9. Distler, J HW, Jungel, A., Huber, L. C., Schulze-Horsel, U., Zwerina, J. Gay, R. E. et al. (2007) Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum, 56, pp. 311-322.
10. Banovic, T., MacDonald, K. P., Morris, E. S., Rowe, V., Kuns, R. Don, A. et al. (2005) TGF-β in allogeneic stem cell transplantation: Friend or foe?. Blood, 106, pp. 2206-2214.
11. Svegliati, S., Olivieri, A., Campelli, N., Luchetti, M., Poloni, A. Trappolini, S. et al. (2007) Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood, 110, pp. 237-241.
12. Baroni, S. S., Santillo, M., Bevilacqua, F., Luchetti, M., Spadoni, T. Mancini, M. et al. (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med, 354, pp. 2667-2676.
13. Clements, P. J., Lachenbruch, P. A., Seibold, J. R., Zee, B., Steen, V. D. Brennan, P. et al. (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol, 20, pp. 1892-1896.
14. Evangelou, K., Kotsinas, A., Mariolis-Sapsakos, T., Giannopoulos, A., Tsantoulis, P. K. Constantinides, C. et al. (2008) E2F-1 overexpression correlates with decreased proliferation and better prognosis in adenocarcinomas of Barrett oesophagus. J Clin Pathol, 61, pp. 601-605.
15. Magro, L., Catteau, B., Coiteux, V., Bruno, B., Jouet, J. P. and Yakoub-Agha, I. (2008) Efficacy of imatinib mesylate in the treatment of refracory sclerodermatous GVHD. Bone Marrow Transplant, 42, pp. 757-760.
16. Akhmetshina, A., Dees, C., Pileckyte, M., Maurer, B., Axmann, R. Jungel, A. et al. (2008) Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis. FASEB J, 22, pp. 2214-2222.